Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository

Published: Thursday, February 16, 2012
Last Updated: Wednesday, March 07, 2012
Bookmark and Share
Rutgers University Cell and DNA Repository has adopted PerkinElmer’s technologies for automation of Next Generation Sequencing sample preparation.

Next Generation Sequencing (NGS) research has the potential to greatly advance knowledge and facilitate data sharing in identifying the causes of disease, in developing potential disease therapies, as well as in possible clinical diagnostic innovations. The combination of PerkinElmer’s sample library automation with Rutgers’ world-renowned biorepository will make millions of biological samples accessible to researchers worldwide, to help enable large-scale genomic and disease-related studies.

The PerkinElmer NGS laboratory pipeline preparation solutions will enable the Rutgers University Cell and DNA Repository (RUCDR) to perform quality control (QC) on 25,000 DNA samples per week, and prepare hundreds of DNA and RNA sequence libraries per week. The products in use include:

• Sciclone® NGS Workstation – automated solution for high-throughput sequencing sample preparation, to be used for library preparation and RNA sequencing.
LabChip® GX Nucleic Acid Separations System – microfluidics system, to be used for RNA sample quality control and DNA library quality control.
LabChip® DS Microplate Reader – to be used for quality control of extracted biological material.
Twister® II Microplate Handler – a high capacity plate stacker, to feed biological samples through the LabChip DS reader.

Kevin Hrusovsky, president, Life Sciences & Technology, PerkinElmer, said, “PerkinElmer is very proud to be selected by Rutgers for this milestone project in revolutionizing Next Generation Sequencing research. We are excited to be collaborating with a true pioneer in the field of biobanking for NGS as Rutgers makes its millions of samples available to fuel the life sciences research community’s fastest growing and most exciting technique for basic biological research and disease research.”

Dr. Andrew Brooks, associate professor of genetics and chief operating officer, Rutgers University Cell and DNA Repository, said, “Going forward, the RUCDR will have the capacity to prepare every biological sample coming into the repository for automated sequencing applications. This will help expedite research projects, ensure comparable data quality across analytical centers, and facilitate large-scale access and use of clinically-relevant samples across a variety of NIH, foundation and industry funded projects. As preserving prepared libraries of patient samples is becoming a new standard practice for accelerating NGS studies, it is our intention to continue to be the leader in providing researchers with unparalleled access to high quality nucleic acid and cellular material to make potential therapies and diagnostics more powerful and accurate. Without this critical relationship with PerkinElmer, we would not have been able to achieve these goals as efficiently as we have.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ViaCord® Collaborates with the Center for International Blood and Marrow Transplant Research®
PerkinElmer’s family cord blood banking business and international research organization collaborates to analyze quality and outcomes of cord blood stem cell units.
Wednesday, May 01, 2013
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!